We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (OPTION)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01389271
First Posted: July 8, 2011
Last Update Posted: August 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Bayer
  Purpose
This is an open-label, uncontrolled, prospective long-term observation of Specific Drug in the treatment of patients with pulmonary hypertension up to 4 years. 160 patients with primary (idiopathic and familial) pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV planned to enroll. Efficacy, safety and tolerability of the drug and the survival of the patients will be observed.

Condition Intervention
Pulmonary Hypertension Drug: Ventavis inhaled (Iloprost, BAYQ6256)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Open-label, Uncontrolled, Prospective Long-term Observation of Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • 6 Minutes walking distance (change in meters) [ Time Frame: At month 48 ]
  • Adverse events, weight, vital findings [ Time Frame: At month 48 ]

Secondary Outcome Measures:
  • 6 Minutes walking distance (% change) [ Time Frame: At month 48 ]
  • New York Heart Association Functional Class [ Time Frame: At month 48 ]
  • Change in drug dosage or frequency, need for PAH specific drug combination, need for drug change [ Time Frame: At month 48 ]
  • Pulmonary hypertension related hospitalization [ Time Frame: At month 48 ]
  • Heart and/or lung transplantation, mortality [ Time Frame: At month 48 ]

Enrollment: 118
Actual Study Start Date: February 3, 2011
Estimated Study Completion Date: September 12, 2017
Estimated Primary Completion Date: September 12, 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Ventavis inhaled (Iloprost, BAYQ6256)
Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Primary (idiopathic and familial) pulmonary hypertension and PAH secondary to scleroderma without significant interstitial pulmonary disease classified as New York Heart Association (NYHA) functional class III and IV
Criteria

Inclusion Criteria:

  • Patients who has pulmonary hypertension treated with inhaled iloprost older than 18 years old.
  • Primary (idiopathic and familial) pulmonary hypertension (PH) with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV.
  • Pulmonary arterial hypertension (PAH) due to scleroderma with New York Heart Association (NYHA) functional class and exercise capacity, defined as class III and IV.
  • Patients who signed written informed consent.

Exclusion Criteria:

  • Severe coronary heart disease or unstable angina; Myocardial infarction within the last six months; Decompensated cardiac failure if not under close medical supervision;
  • Severe arrhythmias;
  • Cerebrovascular events (e.g. transient ischaemic attack, stroke) within the last 3 months.
  • Pulmonary hypertension due to venous occlusive disease.
  • Congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension.
  • Pregnancy and lactation
  • Age below 18
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01389271


Locations
Turkey
Many Locations, Turkey
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01389271     History of Changes
Other Study ID Numbers: 14990
VE0910TR ( Other Identifier: Company internal )
First Submitted: June 27, 2011
First Posted: July 8, 2011
Last Update Posted: August 15, 2017
Last Verified: August 2017

Keywords provided by Bayer:
Pulmonary hypertension
Inhaled iloprost
Efficacy
Safety
Tolerability
Survival
NYHA class III and IV

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Iloprost
Platelet Aggregation Inhibitors
Vasodilator Agents